ABSTRACT
<p><b>BACKGROUND</b>Urotensin II (UII), a potent vasoconstrictive peptide, is able to stimulate phenotypic differentiation of adventitial fibroblasts. This study aimed to determine the effect of UII on monocyte chemoattractant protein-1 (MCP-1) expression in rat aortic adventitial fibroblasts, so as to explore possible mechanisms in the development of vascular inflammation.</p><p><b>METHODS</b>Growth-arrested adventitial fibroblasts were incubated in serum-free medium with UII (10(-10)-10(-7) mol/L) and inhibitors of signal transduction pathways for 1 to 24 hours. MCP-1 mRNA and protein expression and secretion were determined by RT-PCR, Western blotting analysis and enzyme-linked immunosorbent assay (ELISA), respectively.</p><p><b>RESULTS</b>UII dose- and time-dependently promoted MCP-1 mRNA and protein expression and secretion in cells, with maximal effect at 10(-8) mol/L at 3 hours for mRNA expression, 24 hours for protein expression in the cells, and 12 hours for protein secretion from the cells. Furthermore, the UII effects were significantly inhibited by treatment with its receptor antagonist SB710411, Rho kinase inhibitor Y27632, protein kinase C (PKC) inhibitor H7, mitogen-activated protein kinase inhibitor PD98059, calcineurin inhibitor cyclosporine A, and the Ca(2+)channel blocker nicardipine.</p><p><b>CONCLUSION</b>UII may stimulate MCP-1 expression in rat aortic adventitial fibroblasts through its receptor and Rho kinase, PKC, mitogen-activated protein kinase, calcineurin and Ca(2+) channel signal transduction, thus contributing to adventitial inflammation.</p>
Subject(s)
Animals , Male , Rats , Adventitia , Cell Biology , Aorta , Cell Biology , Cells, Cultured , Chemokine CCL2 , Genetics , Metabolism , Fibroblasts , Metabolism , RNA, Messenger , Genetics , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction , Urotensins , PharmacologyABSTRACT
Objective To investigate the efficacy and safety of oestradiol valerate (E2V) combined with dienogest (DNG) for menorrhagia without organic pathology.Methods Sixty-two menorrhagia without organic pathology patients were randomized divided into observation group (31 cases ) and control group (31cases).E2V combined with DNG were given in observation group while control group with E2V only.Both of the treatment lasted for 3 cycles.The changes in menstrual blood loss was assessed by the pictorial blood loss assessment chart (PBAC).The time of control bleeding,stop bleeding,the level of hemoglobin and adverse reaction were compared.Results The time of control bleeding,stop bleeding in observation group were significantly lower than those in control group[ ( 16.5 ± 2.2) h vs.(23.4 ± 2.9) h,(23.3 ± 8.4) h vs.(40.9 ±4.6) h] (P＜0.01).The level of hemoglobin and PBAC scores between two groups had no significant difference before treatment (P＞0.05).After treatment for 3 cycles,the level of hemoglobin in observation group was higher than that in control group,but had no significant difference (P＞0.05 ),the PBAC scores in observation group was lower than that in control group after treatment for 1,2,3 cycles(P＜0.01 ).Both of the rate of adverse reaction in two groups was 12.9％ (4/31 ).No severe adverse reaction happened in two groups.Conclusions E2V combined with DNG is more rapid and effective in reducing menstrual blood loss.It does not increase the rate of adverse reaction and worthy of clinical application.
ABSTRACT
With the deeply thought of military hospital reform and medical support system,the analysis and suggestions for present situation are put forward.